News & Insights

Google's AI search issue

November 4, 2025

Time to Read: 2:15 mins

In this video, Walter Scott client investment manager George Dent uses Google as a case study to highlight the potential profitability issues facing companies that run artificial intelligence (AI)-driven search functions.

Key points:

Google’s traditional algorithmic search powers its natural monopoly, driven by improved effectiveness with search volume.
But if search is too efficient, there is a risk that users skip sponsored links, eroding ad click-through rates and endangering Google’s revenue model.
AI-driven search boosts results but incurs high compute costs, creating profit uncertainty.
Investors need to be sharp to spot potential emerging winners and losers in this evolving landscape.

2788059 Exp: 12 January 2026

expanding-the-investment-universe-in-global-infrastructure-tile-580x325px

Article | Equities

Beyond the grid: expanding the investment universe in global infrastructure

BNY Investments Newton’s investment strategists Brian Blongastainer and Carolina Ortega explain why they expect to see a major acceleration in global infrastructure spending over the next decade, driven by new investment opportunities fuelled by the growth in artificial intelligence (AI).

Article | Equities

Novo Nordisk: rethinking the playbook

Direct-to-client (DTC) health platforms and personalized compounded treatments may become standard practice in the rapidly evolving obesity treatment market. Walter Scott investment analyst Dr Oriana Beaumont believes that Novo Nordisk’s recent changes will help position them to effectively compete in this exciting and vast market.

Report | Macroeconomic

Recalculating route

BNY's commitment to insight and perspectives comes to life through our investment and market leaders who gather quarterly to debate the key issues shaping markets today.

IFMH | Equities

Where next for Novo Nordisk?

In this video, Walter Scott client investment manager Murdo MacLean considers Novo Nordisk’s recent challenges and touches on what the future could look like for the Danish pharma giant.